Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lyell Immunopharma Inc LYEL

Healthcare Biotechnology
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LYEL)

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

GlobeNewswire November 7, 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 5, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

GlobeNewswire October 31, 2024

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

GlobeNewswire October 24, 2024

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire October 4, 2024

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

GlobeNewswire September 24, 2024

Lyell Immunopharma Announces Participation in September Investor Conferences

GlobeNewswire August 28, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

GlobeNewswire August 7, 2024

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

GlobeNewswire June 26, 2024
View More News ››

Opinion & Analysis (NDAQ:LYEL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LYEL)

Lyell Immunopharma Shares Plunge On One Patient Death In CAR

Just In: $LYEL Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial | BenzingaLyell Immunopharma Inc...
whytestocks - June 26, 2024
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Montney-focused oil and natural gas exploration and development company, with lands located in ...
View More »